The results of a phase I / II study of INTUVAX® indicates that the vaccine can enhance the body’s immune system and thereby prolong survival in renal cancer. Additionally observed signs of synergistic effect with tyrosine kinase inhibitors – a different kind of drugs against tumor diseases. No confirmed vaccine-related adverse events were recorded.
- Bli medlem
- Om SwedenBIO